Shattuck Labs, Inc. (STTK) Stock Price & Analysis
Shattuck Labs, Inc. (STTK) rose 9.49% to USD 4.27 as of June 10, 2026 at 02:25 UTC, according to Nexqual real-time market data.
STTK last closed at USD 3.9; the session ranged USD 3.97–4.67 on volume of 1,457,309 shares. Market capitalization is $327.43M, with a 52-week range of USD 0.71–8.33 (NMS). Source: Nexqual, June 10, 2026 at 02:25 UTC.
Key Statistics (as of June 10, 2026 at 02:25 UTC)
| Price | USD 4.27 |
|---|---|
| Change | ▲ 9.49% (up) |
| Previous Close | USD 3.9 |
| Open | USD 4.08 |
| Day Range | USD 3.97 – 4.67 |
| 52-Week Range | USD 0.71 – 8.33 |
| Volume | 1,457,309 shares |
| Market Cap | $327.43M |
| Exchange | NMS |
Technical Analysis (STTK)
Nexqual's technical model rates STTK "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24.74 (oversold) |
| vs SMA50 | Below (USD 6.49) |
| MACD | -0.61 (negative) |
Analyst Ratings (STTK)
Wall Street analysts rate STTK "Strong Buy" based on 6 analysts, with a mean price target of USD 14.83 (range USD 10–18), per Nexqual as of June 10, 2026 at 02:25 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 14.83 |
| High Target | USD 18 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (STTK)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.13 ▲ beat |
| 2025-12-31 | USD -0.12 vs est -0.13 ▲ beat |
| 2025-09-30 | USD -0.14 vs est -0.15 ▲ beat |
| 2025-06-30 | USD -0.24 vs est -0.25 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financials & Fundamentals (STTK)
| Total Revenue | $1.00M |
|---|---|
| Gross Margin | -297.80% |
| Operating Margin | -5258.30% |
| Profit Margin | +0.00% |
| ROE | -61.04% |
| Debt / Equity | 3.02 |
| Current Ratio | 22.07 |
| Total Cash | $90.42M |
| Total Debt | $2.89M |
| Free Cash Flow | $-22.42M |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Financial Health Score (STTK)
Nexqual rates Shattuck Labs, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:25 UTC.
| Growth | Critical — Revenue -83% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $90M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$22M, burning cash |
| Efficiency | Critical — ROE -61%, ROA -36.7% |
Ownership (STTK)
| Insider Ownership | +5.26% |
|---|---|
| Institutional Ownership | +73.20% |
| Shares Outstanding | 76.68M |
| Float | 47.71M |
| Short % of Float | +1.57% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
Leadership (STTK)
Shattuck Labs, Inc. is led by Taylor H. Schreiber (age 45), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 02:25 UTC.
| Co-Founder, CEO & Director | Taylor H. Schreiber (age 45) |
|---|---|
| Chief Financial Officer | Andrew R. Neill (age 39) |
| Vice President of Accounting & SEC reporting | Brad Huckabee |
| Senior Vice President of Regulatory Affairs | Thomas Lampkin Pharm.D. |
| Chief Scientific Officer | Suresh de Silva |
Major Backers & Investors (STTK)
Notable institutional backers of Shattuck Labs, Inc. include T. Rowe Price, Orbimed Advisors LLC., Redmile Group, LLC, according to Nexqual as of June 10, 2026 at 02:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 22.43% |
| Orbimed Advisors LLC. | 8.22% |
| Redmile Group, LLC | 7.22% |
| Prosight Management, Lp | 6.53% |
| Adage Capital Partners GP L.L.C. | 6.06% |
| Price (T.Rowe) Associates Inc | 5.96% |
| Nextbio Capital Management LP | 4.11% |
| Clark Estates Inc. (The) | 1.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.86% |
Source: Nexqual, June 10, 2026 at 02:25 UTC.
From Shattuck Labs, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property We strive to protect and enhance our proprietary technology, inventions, and improvements that we consider commercially important to the development of our business, including by seeking, maintaining, and defending U.S. and foreign patent rights, including patents covering our platform technologies, product candidates, and methods of using the same, whether developed internally or licensed from third parties.
- This agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.
- We also rely on trade secrets, know-how, and continuing technological innovation to develop, strengthen and maintain our proprietary position in our field.
Partnerships
- Because DR3 is a membrane-restricted target, immune complex formation is not expected either for SL-325, SL-425, or DR3 directed bispecific antibodies. 7 Manufacturing and Supply By working with third-party vendors to conduct activities in compliance with current Good Manufacturing Practices ("cGMP"), we have invested significant resources to identify and scale up a suitable manufacturing process for our product candidates, including SL-325.
- We manufacture bulk drug substance ("BDS") for SL-325 utilizing the services of a single third-party contract manufacturer, Kemwell Biopharma Private Limited ("Kemwell"), with whom we maintain a master service agreement, pursuant to which Kemwell manufactures BDS on a per project basis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | USD 3.58 | ▼ 7.01% |
| PRLD | Prelude Therapeutics Incorporat | USD 3.94 | ▲ 3.41% |
| FHTX | Foghorn Therapeutics Inc. | USD 3.87 | ▲ 3.75% |
| TSHA | Taysha Gene Therapies, Inc. | USD 5.36 | ▼ 2.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:25 UTC. This page is informational and not investment advice.